Health Yuan Innovation contributes to a 'Healthy China' initiative, safeguarding the respiratory health of hundreds of millions.
Published Time:
2025-03-11
Against the backdrop of intensifying global public health challenges, China is accelerating the advancement of the "Healthy China 2030" strategy to improve the overall health of its population and optimize the management system for chronic diseases. The agenda of the National People's Congress and Chinese People's Political Consultative Conference in 2025 also focused on chronic disease prevention and control, optimization of primary-level medical resources, and the construction of the public health system, providing policy support for the innovative development of the pharmaceutical industry. As a leading domestic enterprise in the respiratory field, Jiankangyuan Pharmaceutical Group is leveraging technological innovation to comprehensively develop a respiratory disease prevention and control system, contributing to national public health construction, and promoting the Chinese pharmaceutical industry to occupy a leading position in global competition.


Policy Advancement for COPD
Jiankangyuan Accelerates the Layout of a Full-Scenario Innovation Matrix
Chronic Obstructive Pulmonary Disease ( COPD) has become one of the major global public health problems. In August 2023, the country included COPD in the basic public health service projects, providing policy support for early screening, early diagnosis, and standardized treatment. Data shows that there are more than 100 million COPD patients and more than 60 million asthma patients in China. Facing huge clinical needs, Jiankangyuan has built a full-scenario innovation matrix covering bio-innovative drugs, oral medications, inhalation preparations, and anti-infective drugs and continues to cultivate and accelerate breakthroughs in the field of precise treatment of respiratory diseases.
Jiankangyuan's clear innovative drug R&D approach: Focusing on new targets and new mechanisms, a comprehensive layout of inhalation preparations, oral medications, and injections for COPD and respiratory diseases is being developed. In recent years, the company has continuously accelerated the advancement of its innovative product pipeline, from tobramycin inhalation solution (Jianketo®) to mavacamten, ®)到玛帕西沙韦 Jiankangyuan's innovation strategy is accelerating its implementation.

Accelerated Advancement of the Innovation Pipeline
Consolidating the Precise Treatment Layout for COPD
In October 2022, Jiankangyuan's independently developed tobramycin inhalation solution (Jianketo®) was approved for marketing, filling the gap in the domestic inhaled antibiotic market. This breakthrough not only elevated Jiankangyuan's leading position in the domestic respiratory preparation field but also marked the beginning of the harvest period for its innovative development strategy.
Based on a clear strategic approach, Jiankangyuan's innovative layout is rapidly unfolding. In the first quarter of 2024, the company successively launched targeted TSLP monoclonal antibody innovative drug (for the treatment of moderate to severe asthma /COPD), targeted long-acting IL-4R monoclonal antibody (for the treatment of moderate to severe asthma /COPD), and targeted PREP oral COPD innovative drug . Among them, the TSLP target is a popular direction in the global COPD treatment field. Studies have shown that related products can effectively reduce the number of acute exacerbations in patients with moderate to severe COPD. At the same time, the PREP oral drug is expected to fill the gap in the Chinese market and become the first domestically produced oral innovative drug for the treatment of COPD.
In addition, Jiankangyuan continues to optimize its inhalation preparation product matrix to further improve the accuracy and convenience of chronic disease management. In September, the company launched research on a new generation of glucocorticoids focusing on the optimized treatment of COPD, asthma, and rhinitis, aiming to improve efficacy while reducing the side effects of glucocorticoid drugs. In November, the developed PDE4 inhibitor inhalation preparation will provide a gentler anti-inflammatory treatment option for patients with lower tolerance.
In terms of anti-infective treatment, Jiankangyuan is also continuously advancing the precise prevention and control of COPD combined with infection 上持续推进。 In December, the company actively promoted research on β-lactamase inhibitors combined with meropenem to provide more efficient treatment options for the risk of acute exacerbation caused by repeated infections in COPD patients. At the same time, the mavacamten influenza antiviral drug which was submitted for production in August, can inhibit influenza A and B viruses with a single oral dose, providing additional protection for patients with chronic respiratory diseases during the influenza season and reducing the risk of disease worsening.
Currently, Jiankangyuan holds more than 20 innovative drugs covering a wide range of respiratory diseases, anti-infective agents, and other fields. These innovative products are accelerating clinical advancement, and many projects are leading in domestic progress.


Intelligent Innovation, Contributing to a Healthy Future
As the pharmaceutical industry moves towards intelligence and digitalization, Jiankangyuan continues to promote the application of AI in new drug R&D, supply chain management, and enterprise operations. In December 2024, the company comprehensively upgraded its AI technology to improve R&D efficiency and refined management levels , using AI to accelerate clinical data analysis, patient stratification research, and drug screening, further shortening the R&D cycle and improving the efficiency of innovative drug launches. In the future, Jiankangyuan will continue to use technological innovation as its engine, working with partners from all walks of life to contribute to China's respiratory disease prevention and control system.